OXT and Hyperbilirubinemia: Specifically, compared with the high-dose group, the risk of hyperbilirubinemia in the moderate-dose group was significantly lower (OR: 0.39, 95% CI: 0.196–0.776, p = 0.007) and lowest in the low-dose group (OR: 0.128, 95% CI: 0.047–0.346, p < 0.001), confirming that higher oxytocin doses were associated with increased risk.